GNH USA

Europe — EMA

Mitoxantron Accord (Mitoxantrone)

GNH USA supplies Mitoxantron Accord (Mitoxantrone), a anthracenedone antineoplastic agent for acute myeloid leukemia, metastatic breast cancer and other

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxantron Accord, is a anthracenedone presented as a intravenous solution for intravenous use. It treats certain cancers such as acute myeloid leukemia, metastatic breast cancer, prostate cancer and non‑Hodgkin lymphoma in adult patients.

GNH USA supplies Mitoxantron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Mitoxantrone used for?

Mitoxantrone is used in oncology to target rapidly proliferating malignant cells.

Acute Myeloid Leukemia: used as part of induction or salvage therapy to achieve remission. Metastatic Breast Cancer: administered to control disease progression in patients with advanced disease. Prostate Cancer: employed in hormone‑refractory cases to improve survival. Non‑Hodgkin Lymphoma: incorporated into combination regimens for refractory or relapsed disease.

What are the side effects of Mitoxantrone?

Mitoxantron Accord may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Alopecia (hair loss) - Myelosuppression, including neutropenia and anemia

Serious or Rare Side Effects: - Cardiotoxicity, manifested as reduced left‑ventricular ejection fraction - Secondary acute myeloid leukemia - Severe infections due to profound neutropenia - Hepatic toxicity with elevated transaminases - Pulmonary fibrosis or interstitial lung disease

What precautions apply to Mitoxantrone?

Mitoxantron Accord requires careful monitoring before and during therapy.

Cardiac monitoring: baseline and periodic ejection‑fraction assessment due to risk of cardiotoxicity. Hematologic monitoring: regular complete blood counts to detect myelosuppression. Renal function: assess before and during treatment as clearance may be affected. Pregnancy and lactation: avoid use unless benefits outweigh risks; limited data are available. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantron Accord can interact with several drug classes.

Major Interactions (Avoid): - Anthracyclines: concurrent use increases risk of cardiotoxicity. - Chest radiation therapy: may exacerbate cardiac damage. - Live vaccines: immunosuppression may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may raise plasma levels of mitoxantrone. - CYP3A4 inhibitors: potential for increased exposure. - Nephrotoxic agents: monitor renal function closely.

Frequently asked questions

What is Mitoxantron Accord used for?+
Mitoxantron Accord contains mitoxantrone, an anthracenedone antineoplastic agent indicated for the treatment of acute myeloid leukemia, metastatic breast cancer, prostate cancer and non‑Hodgkin lymphoma. It is employed in adult patients as part of combination chemotherapy regimens to achieve disease control or remission.
How does mitoxantrone work?+
Mitoxantrone intercalates into DNA and blocks the activity of topoisomerase II, an enzyme required for DNA unwinding during replication. By preventing DNA strand re‑ligation, the drug induces double‑strand breaks, leading to apoptosis of rapidly dividing cancer cells while sparing most normal tissues.
What is the usual dose of Mitoxantron Accord?+
The dosage of Mitoxantron Accord is individualized and determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and cardiac function, and treatment protocol. Healthcare professionals adjust the dose to balance efficacy with safety.
Is Mitoxantron Accord safe in pregnancy or breastfeeding?+
Data on mitoxantrone use during pregnancy and lactation are limited. Because the drug can cross the placenta and may cause fetal harm, it is generally avoided unless the potential benefit justifies the risk. Breastfeeding is not recommended while receiving treatment.
How do I order Mitoxantron Accord from GNH USA?+
To place an enquiry, visit the product page on gnh-usa.com, enter the required quantity and submit the request. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.
How does Mitoxantron Accord compare with the main alternative drug or class?+
Mitoxantrone belongs to the anthracenedone class, similar to drugs such as doxorubicin and etoposide. Compared with etoposide, mitoxantrone has a longer intracellular half‑life and may cause less severe nausea but carries a higher risk of cardiotoxicity. Choice of therapy depends on tumor type, prior treatment history and patient comorbidities.
What are the storage and handling requirements for Mitoxantron Accord?+
Mitoxantron Accord must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If a temporary temperature excursion occurs, consult the product’s stability data before use.
How is Mitoxantron Accord administered?+
The product is supplied as an intravenous solution and is administered by slow infusion through a peripheral or central line under the supervision of qualified medical staff. Infusion duration and rate are prescribed by the oncologist and may be adjusted according to patient tolerance and cardiac monitoring results.
What are the most serious risks to watch for while receiving Mitoxantron Accord?+
The most critical adverse events include cardiotoxicity (reduced left‑ventricular function), secondary acute myeloid leukemia, severe myelosuppression leading to infections or bleeding, hepatic toxicity, and pulmonary fibrosis. Patients should undergo regular cardiac imaging, blood counts and liver function tests throughout therapy.
Who should not use Mitoxantron Accord?+
Mitoxantron Accord is contraindicated in patients with known hypersensitivity to mitoxantrone or any formulation component, those with severe pre‑existing cardiac dysfunction (e.g., ejection fraction < 50 %), uncontrolled active infections, and individuals who are pregnant unless the therapeutic benefit outweighs the risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Accord Healthcare B.V.
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU